T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
TL;DR: The potential of using bladder cancer as a model to investigate cancer immune response mechanisms and new therapeutic approaches, which may be translated into immunotherapy of other human cancers, is explored.
Journal ArticleDOI
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.
Zia Khan,F. Di Nucci,Antonia Kwan,Christian Hammer,Sanjeev Mariathasan,Vincent Rouilly,J. D. Carroll,Magnus Fontes,Sergio Ley Acosta,Ellie Guardino,Haiyin Chen-Harris,Tushar Bhangale,Ira Mellman,Jonathan Rosenberg,Thomas Powles,Julie Hunkapiller,G. Scott Chandler,Matthew L. Albert +17 more
TL;DR: It is found that genetic variants that confer risk for dermatological autoimmunity impact patient survival, as compared to chemotherapy, and risk of skin toxicity during treatment, following anti-PD-L1 monotherapy in bladder cancer.
Journal ArticleDOI
Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.
Arjun Vasant Balar,Daniel Castellano,Peter H. O'Donnell,Petros Grivas,Jacqueline Vuky,Thomas Powles,Elizabeth R. Plimack,Noah M. Hahn,Ronald de Wit,Lei Pang,Mary J. Savage,Rodolfo F. Perini,Stephen Michael Keefe,Dean F. Bajorin,Joaquim Bellmunt +14 more
TL;DR: First-line pembrolizumab (pembro) had antitumor activity and acceptable safety in this pt population suggested in the phase 2, open-label KEYNOTE-052 study.
Journal ArticleDOI
Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Nizar M. Tannir,Osvaldo Arén Frontera,Hans J. Hammers,Michael A. Carducci,David F. McDermott,Pamela Salman,Bernard Escudier,Benoit Beuselinck,Asim Amin,Camillo Porta,Saby George,Sergio Bracarda,Scott S. Tykodi,Thomas Powles,Brian I. Rini,Yoshihiko Tomita,M. Brent McHenry,Sabeen Mekan,Robert J. Motzer +18 more
TL;DR: At 30 mo min follow-up, OS remains significantly improved in ITT and I/P pts with N+I v S; the HR for OS in favorable (fav) risk pts has improved for N-I v the previous analysis, and increasing PFS benefit with N+.
Journal ArticleDOI
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids
Reyes Gonzalez-Exposito,Maria Semiannikova,Beatrice Griffiths,Khurum Khan,Louise J. Barber,Andrew Woolston,Georgia Spain,Katharina von Loga,Ben Challoner,Radhika Patel,Michael Ranes,Amanda Swain,Janet Thomas,Annette Bryant,C. Saffery,Nicos Fotiadis,Sebastian Guettler,David Mansfield,Alan Melcher,Thomas Powles,Sheela Rao,David Watkins,Ian Chau,Nik Matthews,Fredrik Wallberg,Naureen Starling,David Cunningham,Marco Gerlinger,Marco Gerlinger +28 more
TL;DR: Heterogeneity and plasticity of CEA expression appear to confer low cibisatamab sensitivity in PDOs, supporting further clinical evaluation of their predictive effect in CRC and pharmacological inhibition of the WNT/β-catenin pathway may be a rational combination to sensitize CRCs to cibISatamAB.